Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Fremont Memorial Hospital
mi
from
Fremont, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Fremont Memorial Hospital
mi
from
Fremont, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Kenton Oncology, Incorporated
mi
from
Kenton, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Kenton Oncology, Incorporated
mi
from
Kenton, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Lima Memorial Hospital
mi
from
Lima, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Lima Memorial Hospital
mi
from
Lima, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Luke's Hospital
mi
from
Maumee, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Luke's Hospital
mi
from
Maumee, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Toledo Clinic - Oregon
mi
from
Oregon, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Toledo Clinic - Oregon
mi
from
Oregon, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Firelands Regional Medical Center
mi
from
Sandusky, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Firelands Regional Medical Center
mi
from
Sandusky, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Promedica Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Promedica Cancer Center at Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Toledo Surgical Specialists
mi
from
Toledo, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Toledo Surgical Specialists
mi
from
Toledo, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Allegheny Cancer Center at Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
AnMedical Health Cancer Center
mi
from
Anderson, SC
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited at St. Vincent Hospital
mi
from
Green Bay, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited at St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer
Status: Enrolling
Updated:  7/14/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer
Status: Enrolling
Updated: 7/14/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Chicago
mi
from
Chicago, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
New York University Langone Medical Center
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials